{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:29:00Z","timestamp":1794475740028,"version":"4.9.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015616","name":"Gray Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015616","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ygyno.2026.04.010","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T22:25:04Z","timestamp":1777069504000},"page":"7-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pathway-level somatic mutation burden reflects diffuse genomic accumulation rather than selective transcriptional disruption in ovarian serous carcinoma: Evidence from bulk, spatial, and multi-region genomic analyses"],"prefix":"10.1016","volume":"209","author":[{"given":"Elif Kardelen","family":"\u00c7a\u011fda\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7793","key":"10.1016\/j.ygyno.2026.04.010_bb0005","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41586-020-1970-0","article-title":"Genomic basis for RNA alterations in cancer","volume":"578","author":"Calabrese","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ygyno.2026.04.010_bb0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"issue":"1","key":"10.1016\/j.ygyno.2026.04.010_bb0015","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1634\/theoncologist.2019-0244","article-title":"Tumor mutational burden as a predictive biomarker for response to immune checkpoint inhibitors","volume":"25","author":"Klempner","year":"2020","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.ygyno.2026.04.010_bb0020","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients treated with pembrolizumab","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"issue":"43","key":"10.1016\/j.ygyno.2026.04.010_bb0025","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2026.04.010_bb0030","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3389\/fonc.2018.00658","article-title":"Pathway instability is an effective new mutation-based type of cancer biomarkers","volume":"8","author":"Zolotovskaia","year":"2018","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.04.010_bb0035","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ygyno.2026.04.010_bb0040","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s40425-019-0647-4","article-title":"Tumor mutational burden quantification from targeted gene panels","volume":"7","author":"Fancello","year":"2019","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2026.04.010_bb0045","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1186\/s12885-022-09897-3","article-title":"Bias and inconsistency in the estimation of tumour mutation burden","volume":"22","author":"Makrooni","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2026.04.010_bb0050","doi-asserted-by":"crossref","first-page":"8971","DOI":"10.1038\/ncomms9971","article-title":"Systematic pan-cancer analysis of tumour purity","volume":"6","author":"Aran","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2026.04.010_bb0055","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1038\/ncomms3612","article-title":"Inferring tumour purity and stromal and immune cell admixture from expression data","volume":"4","author":"Yoshihara","year":"2013","journal-title":"Nat. Commun."},{"issue":"7457","key":"10.1016\/j.ygyno.2026.04.010_bb0060","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nature12213","article-title":"Mutational heterogeneity in cancer and the search for new cancer-associated genes","volume":"499","author":"Lawrence","year":"2013","journal-title":"Nature"},{"issue":"7353","key":"10.1016\/j.ygyno.2026.04.010_bb0065","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ygyno.2026.04.010_bb0070","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/path.2696","article-title":"Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary","volume":"221","author":"Ahmed","year":"2010","journal-title":"J. Pathol."},{"issue":"12","key":"10.1016\/j.ygyno.2026.04.010_bb0075","first-page":"2410","article-title":"Spatially resolved multi-omic characterization of high-grade serous ovarian carcinoma","volume":"14","author":"Kader","year":"2024","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.ygyno.2026.04.010_bb0080","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0092-8674(00)00030-1","article-title":"BRCA1 is associated with a human SWI\/SNF-related complex: linking chromatin remodeling to breast cancer","volume":"102","author":"Bochar","year":"2000","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.ygyno.2026.04.010_bb0085","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/ng.2628","article-title":"Proteomic and bioinformatic analysis of mammalian SWI\/SNF complexes identifies extensive roles in human malignancy","volume":"45","author":"Kadoch","year":"2013","journal-title":"Nat. Genet."},{"issue":"3","key":"10.1016\/j.ygyno.2026.04.010_bb0090","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ccr.2014.07.018","article-title":"Vulnerabilities of mutant SWI\/SNF complexes in cancer","volume":"26","author":"Helming","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2026.04.010_bb0095","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pharmthera.2018.05.001","article-title":"ARID1A loss in cancer: towards a mechanistic understanding","volume":"190","author":"Mathur","year":"2018","journal-title":"Pharmacol. Ther."},{"issue":"27","key":"10.1016\/j.ygyno.2026.04.010_bb0100","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1038\/onc.2009.121","article-title":"The SWI\/SNF chromatin remodeling subunit BRG1 is a critical regulator of p53 necessary for proliferation of malignant cells","volume":"28","author":"Naidu","year":"2009","journal-title":"Oncogene"},{"issue":"7941","key":"10.1016\/j.ygyno.2026.04.010_bb0105","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","article-title":"Ovarian cancer mutational processes drive site-specific immune evasion","volume":"612","author":"V\u00e1zquez-Garc\u00eda","year":"2022","journal-title":"Nature"},{"issue":"7269","key":"10.1016\/j.ygyno.2026.04.010_bb0110","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08460","article-title":"Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1","volume":"462","author":"Barbie","year":"2009","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ygyno.2026.04.010_bb0115","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/modpathol.2011.183","article-title":"Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma","volume":"25","author":"Soslow","year":"2012","journal-title":"Mod. Pathol."},{"issue":"16","key":"10.1016\/j.ygyno.2026.04.010_bb0120","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ygyno.2026.04.010_bb0125","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1158\/2159-8290.CD-14-0849","article-title":"ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors","volume":"5","author":"Shen","year":"2015","journal-title":"Cancer Discov."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826019554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825826019554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:00:15Z","timestamp":1794474015000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825826019554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":25,"alternative-id":["S0090825826019554"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.04.010","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathway-level somatic mutation burden reflects diffuse genomic accumulation rather than selective transcriptional disruption in ovarian serous carcinoma: Evidence from bulk, spatial, and multi-region genomic analyses","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}